The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727).
E. Jonasch
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Pfizer
P. Lara
Consultant or Advisory Role - Novartis
N. M. Tannir
Consultant or Advisory Role - Abbott Laboratories; Pfizer
Honoraria - Abbott Laboratories; Pfizer
Research Funding - Pfizer